Why the study?
Does dipyridamole alone or in combination with aspirin improve secondary prevention of arterial thrombosis compared to aspirin alone?
Does dipyridamole alone or in combination with aspirin improve secondary prevention of arterial thrombosis compared to aspirin alone?
Historically, dipyridamole alone or combined with aspirin has not shown significant benefit over aspirin alone for secondary prevention of arterial thrombosis.
Answers are grounded in this paper and cite their sources.
Supports aspirin monotherapy for secondary prevention; leaves open whether updated analyses alter this conclusion.
Although dipyridamole was identified as a potential antithrombotic agent many years ago,(1) its effectiveness as a single agent in secondary prevention of arterial thrombosis in man has never been proven in properly conducted clinical trials with sufficient power. In many clinical trials it has been tested in combination with aspirin, and until recently meta-analyses have failed to show any significant benefit of the combination of aspirin and dipyridamole beyond that shown with aspirin alone.(2,3).
No takes yet. Share an insight, caveat, or question.
Stan Heptinstall (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: